Chemotherapy response assessment in stage IV melanoma patients—comparison of 18F-FDG-PET/CT, CT, brain MRI, and tumormarker S-100B by Strobel, Klaus et al.
ORIGINAL ARTICLE
Chemotherapy response assessment in stage IV
melanoma patients—comparison of 18F-FDG-PET/CT, CT,
brain MRI, and tumormarker S-100B
Klaus Strobel & Reinhard Dummer & Hans C. Steinert &
Katrin Baumann Conzett & Karin Schad &
Marisol Pérez Lago & Jan D. Soyka & P. Veit-Haibach &
Burkhardt Seifert & V. Kalff
Received: 14 December 2007 /Accepted: 1 April 2008 / Published online: 6 May 2008
# Springer-Verlag 2008
Abstract
Purpose This study aims to compare the use of 18F-FDG-
PET/CT, CT, brain MRI, and tumormarker S-100B in
chemotherapy response assessment of stage IV melanoma
patients.
Methods In 25 patients with stage IV melanoma, FDG-
PET/CT and S-100B after 2–3 months (three cycles) of
chemotherapy was compared with baseline PET/CT and
baseline S-100B. Retrospectively, the response was corre-
lated with the outcome. In patients with clinical suspicion
for brain metastases, MRI or CCT was performed.
Results There was agreement between FDG-PET/CT and
CT regarding response to chemotherapy in all patients.
There was a clear trend to a longer OS of PET/CT
responders (n=10) compared with PET/CT non-responders
(n=15; p=0.072) with remarkably better 1-year OS of 80%
compared to 40% (p=0.048). There was a significant longer
PFS of PET/CT responders compared with PET/CT non-
responders (p=0.002). S-100B was normal at baseline in
eight of 22 patients where it was available. Chemotherapy
response assessment with S-100B failed to show correlation
with OS or PFS. Eleven patients developed brain metasta-
ses during treatment, first detected by PET/CT in two and
by MRI or CCT in nine of 11 patients. Appearance of brain
metastases was associated with a poor survival.
Conclusions 18F-FDG-PET/CT and CT alone are equally
suitable for chemotherapy response assessment in melano-
ma patients and clearly superior to S-100B. PET/CT
responders have better early survival, but this is shortlived
due to late therapy failure—often with brain recurrence.
Additional brain MRI for therapy response assessment in
such high-risk patients is mandatory to detect brain
metastases missed by PET/CT.
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Introduction
Stage IV melanoma with distant metastases remains an
incurable disease with a poor 5-year survival of 6% [1, 2].
Melanoma metastases are characterized by relevant chemo-
resistance, and the use of systemic therapy for patients with
multiple unresectable distant metastases is still controver-
sial [3, 4]. Many patients with metastases are included in
clinical trials in an attempt to determine any benefit from
new treatment regimes. The currently used drugs have
severe side effects and are expensive. Therefore, methods to
assess the early success or failure of chemotherapy are
important to both the patient and the health care system.
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18F-FDG-PET/CT is increasingly used for initial staging
of patients with high-risk melanoma. 18F-FDG-PET/CT
with its unique combination of metabolic and morphologic
information has a high accuracy for metastases in these
patients and is superior to PET alone, CT alone, or
conventional imaging methods in the M-staging situation
[5–7]. Preliminary studies showed that PET imaging may
help to select the patients for surgery and has influence on
the survival [8]. 18F-FDG-PET and-PET/CT is increasingly
used for neoadjuvant, adjuvant, curative, or palliative chemo-
therapy response assessment in different malignant tumors
such as lymphoma [9–11], esophageal cancer [12, 13], lung
cancer [14], and breast cancer [15], but publications
regarding PET or PET/CT for therapy response assessment
in melanoma patients are still very limited [16, 17].
Serum S-100B is a useful tumormarker in melanoma
patients, indicating the presence of distant metastases and
reflecting the tumor burden. In addition, S-100B has
prognostic implications [18–23].
The aim of this study was to compare the value of 18F-
FDG-PET/CT, CT, brain MRI, and tumormarker S-100B in
chemotherapy response assessment of stage IV melanoma
patients in correlation with the survival.
Materials and methods
Patients
This retrospective study contains 25 consecutive patients
(14 women, 11 men; mean age 62.3 years; range 31–
82 years) which fulfilled the following criteria: diagnosis of
melanoma with proven distant metastases; metastases were
proven by biopsy in 15 patients and by typical appearance
on PET/CT imaging (multiple focal lesions with increased
FDG uptake not fitting to physiological, inflammatory
lesions or other tumors) and/or rising S-100B tumormarker
or other clinical findings in the remaining ten patients. 18F-
FDG-PET/CT was performed at baseline (PET/CT 0) and
after 2–3 months (three cycles) of chemotherapy (PET/CT
1). Contemporaneous S-100B 0 and S-100B 1 measure-
ments were available for comparison with 18F-FDG PET/
CT data in 22 cases. Overall, 14 CCTs and 18 brain MRI
scans were performed if there was a suspicion for brain
metastases. Imaging and therapy of the patients were
performed between September 2004 and September 2007.
We received approval from our institutional review
board to undertake this retrospective study.
Therapy
All the patients had stage IV melanoma with distant
metastases and were included in clinical trials which used
various chemotherapy regimes. In all the patients, the
distant metastases were not detected at primary staging
but during follow-up after resection of the primary tumor.
In two patients, the primary tumor was unknown. The
different localization of the primary tumors, Breslow
thickness, and localizations of the distant metastases are
described in Table 1. All the patients started with a first-line
therapy: nine patients were treated with temozolomide
alone, nine patients with dacarbazine alone, and seven
patients with a combination of dacarbazine and thalido-
mide. In nine patients, first-line chemotherapy was changed
to second-line chemotherapy because of progression of the
metastases. In the most cases, cisplatin and vindesine were
used for second-line treatment. In two patients, additional
immunotherapy was administered. Seven patients under-
went surgery during the follow-up. The localization of the
resected metastases were as follows: lung (n=3), brain (n=
2), stomach, and the inguinal region. Nine patients received
additional radiotherapy of the following localizations: brain
(n=5, one of them together with radiotherapy of a bone
metastasis in the knee), thigh (n=3), and spine (n=1).
Determination and therapy response assessment
with S-100B
The determination of serum S-100B was performed with a
commercially available immunoassay (ELISA) KIT (Sang-
tec 100 ELISA, Dia Sorin, Stillwater, NM, USA) according
to the instructions of the manufacturer. A definitely normal
cut-upper limit was defined as 0.2 μg/l (the 95 percentile of
blood donor samples). Values ≥0.3 μg/l were determined as
indicative of definite melanoma metastases. The detection
limit is 0.03 μl/l (BO+3 SD). Intra-assay and inter-assay
precision was estimated by analysis of variance (ANOVA).
The within and total run reproducibility is within 10%.
In all the patients, S-100B levels were determined before
and during therapy. All together, 87 single S-100B
measurements were performed in 25 patients (mean 3.48
measurements per patient). The percentage change of S-
100B levels between S-100B 0 and S-100B 1 was assessed,
and an increase or decrease of <30% of S-100B during
therapy was determined as no response to chemotherapy, a
decrease of ≥30% or a decrease from pathologically
elevated S-100B value to a normal value (≤0.2 μg/l) was
determined as response to chemotherapy.
PET/CT imaging protocol
All data were acquired on a combined PET/CT in-line
system (Discovery LS or Discovery ST, GE Health
Systems, Milwaukee, WI, USA).
Patients fasted for at least 4 h prior to the scanning,
which started approximately 60 min (median 66 min; range
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54–73 min) after the injection of 370–400 MBq of 18F-
FDG. All the patients were tested for a normal glucose level
before scanning. The patients with elevated glucose levels
were rescheduled and scanned with normal glucose levels. No
intravenous contrast agent was given. Initially, the CT scan
was acquired starting from the level of the head using the
following parameters: 40 mAs, 140 kV, 0.5 s per tube rotation,
slice thickness 4.25 mm, scan length 867 mm, data-
acquisition time 22.5 s. The CT scan was acquired during
breath holding in the normal expiratory position. In the
patients with primary tumors in the lower extremities, the
scanning of the lower legs was added.
Immediately following the CT acquisition, a PET
emission scan was acquired with an acquisition time of
3 min per cradle position with a one-slice overlap in 2D
mode (matrix 128×128). The eight to nine cradle positions
starting from the head to the knees resulted in an
acquisition time of approximately 24–27 min. In the
patients with primary tumors of the lower extremities,
scanning of the lower legs was added. The CT data were
Table 1 Characteristics of 25 patients with chemotherapy response assessment with 18F-FDG-PET/CT, CT and S-100B and follow-up
No Breslow
(mm)
Localization Mets at baseline First-line
chemo
PET/CT
response
CT
response
S-100B
response
Survival
(months)
Follow-up
(months)
Final
tumor load
1 15.0 Thigh Lung, adrenal,
in-transit
TMZ No No Not available 4 High load
2 1.7 Flank Lung, mediastinal,
hilar ln
TMZ Yes Yes Yes 18 Low load,
brain mets
3 4.9 Foot Lung, soft tissue DTIC Yes Yes Yes 18 High load
4 5.5 Arm Lung, ln, soft
tissue, abdominal
DTIC Yes Yes Not suitable 17 No tu
5 6.5 Arm Liver, lung, bone,
ln, pleural effusion
TMZ Yes Yes Yes 19 No tu
6 U Chest Pulmonal DTIC No No Not suitable 10 Low load,
brain mets
7 13.0 Ear Lung, liver TMZ No No No 16 Low load
8 5.3 Knee Lung, liver,
ln, soft tissue
TMZ Yes Yes Yes 12 Only brain
mets
9 6.0 Shoulder Liver, ln DTIC No No No 11 High load
10 8.0 Foot ln mediast
und iliacal
DTIC No No Yes 11 Low load,
brain mets
11 7.0 Arm Lung, bone, ln TMZ No No Not suitable 4 High load
12 1.7 Chin Lung DTIC No No Not suitable 16 No tu
13 3.5 Flank Liver, soft tissue TMZ No No No 9 High load,
brain mets
14 U Rectal Liver, lung,
soft tissue
DTIC Yes Yes Not suitable 15 High load,
brain mets
15 4.3 Abdomen Liver, bone, ln TMZ Yes Yes Yes 7 High load
16 4.1 Knee Lung, in-transit DTIC Yes Yes Yes 14 No tu
17 1.0 Foot Bone, ln TMZ No No Not suitable 5 High load
18 1.8 Arm Lung, liver,
soft tissue
DTIC No No Yes 14 High load,
brain mets
19 U Vagina Pleura,
stomach, ln
DTIC + THAL Yes Yes Not available 24 High load
20 3.5 Back Choledochus,
lung
DTIC + THAL No No Not suitable 16 Low load,
brain mets
21 U Unknown In-transit DTIC + THAL No No No 28 Low load,
brain mets
22 2.1 Arm Lung DTIC + THAL No No Not suitable 17 Low load,
brain mets
23 1.4 Lumbar Lung, liver DTIC + THAL No No Yes 6 Low load,
brain mets
24 2.5 Occipital Lung DTIC + THAL No No No 4 High load
25 U Unknown ln, soft tissue DTIC + THAL Yes Yes Not available 34 Low load,
brain mets
U unknown; ln lymph node; mets metastases; chemo chemotherapy; TMZ temozolomide; DTIC dacarbazine; THAL thalidomide
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used for the attenuation correction, and the images were
reconstructed using a standard iterative algorithm (OSEM).
The acquired images were viewed with a software
providing multiplanar reformatted images of PET alone,
CT alone, and fused PET/CT with linked cursors using AW
workstation (GE Health Systems, Milwaukee, WI, USA).
PET/CT imaging was performed according to the recently
published “procedure guideline for tumor imaging with
18F-FDG PET/CT 1.0” [24].
Overall, 96 PET/CT scans were performed in these 25
patients (mean 3.8 per patient).
Therapy response assessment with CT
The images were reviewed and analyzed by two radiol-
ogists experienced in oncologic CT imaging without
knowledge of other imaging study results. The CT images
were analyzed for the presence and nature of focal
metastatic lesions suspicious for metastases.
For therapy response with CT, the CT part of the 18F-
FDG-PET/CT study was evaluated separately from the PET
part. Response was assessed by comparing the CT part of
PET/CT 0 with PET/CT 1 using the established RECIST
criteria [25]. No response was assigned to (a) patients with
new metastases and/or (b) if there was stability (<30%
decrease of the sum of the longest diameter of the target
lesions) or progression in size of the known metastases. A
therapy response was defined as complete disappearance of
the metastases or at least 30% decrease of the sum of the
longest diameter of the target lesions.
PET/CT interpretation and measurement of SUV max
The 18F-FDG-PET/CT images were reviewed and analyzed
by two experienced nuclear-radiology physicians without
knowledge of the results of other imaging studies. The PET
images and the corresponding CT images of the PET/CTstudy
were analyzed for the presence and nature of focal lesions with
an increased 18F-FDG uptake. For all the patients, the
attenuation-corrected PET images were analyzed. Lesions
were interpreted as metastases if the uptake was higher than
the uptake of the surrounding background tissue, and thus, a
focal lesion was clearly depictable. 18F-FDG uptake in
physiological or benign variants as in muscles or pulmonary
infiltration was excluded from the analysis.
Semiquantitative analysis of FDG uptake in all suspi-
cious lesions was performed by measuring the maximum
standardized uptake value (SUV max).
Therapy response assessment with18F-FDG PET/CT
Response was assessed by comparing the baseline PET/CT
(PET/CT 0) with PET/CT 1 after three cycles of chemo-
therapy. Therapy response assessment with 18F-FDG PET/
CT was determined with a combination of PET and CT
criteria as previously described [16]: Briefly, no response
was defined as increasing FDG uptake in the known
metastases, if new metastases were detected or if there
was no significant decrease of FDG uptake in the known
metastases visible. SUV max measurements were occasion-
ally used if visual evaluation was not sufficient. Chemo-
therapy response was diagnosed if the decrease in size and
FDG uptake of the lesions was more than 30% or complete
disappearance of pathological FDG uptake in the metasta-
ses occurred. The size of the lesions was measured on the
CT part of the PET/CT. If new FDG-negative pulmonary
nodules developed between the baseline and the restaging
investigation, which were not calcified, this was described
as progressive disease due to lung metastases.
Brain imaging with contrast enhanced CCT or MRI
Brain MRI or contrast enhanced CCT was performed at
different institutions in patients with symptoms suspicious
for brain metastases like headache or neurologic deficits or
to confirm 18F-FDG-PET/CT findings which were suspi-
cious for brain metastases. So we do not have PET/CT and
brain MRI contemporaneously in all patients. In all the
patients who received MRI of the brain, at least T2- and
T1-weighted images without contrast and T1-weighted
images with intraveneous application of Gadolinium were
performed. Metastases were diagnosed as contrast-enhancing
parenchymal lesions in T1-weighted images with additional
surrounding edema [26]. CCT was performed according to
established protocols before and after intravenous contrast
administration [27]. Brain images were evaluated by
experienced neuroradiologists.
Statistical analysis
Data were analyzed on a patient basis using SPSS 15 for
Windows (SPSS). Kaplan–Meier curves were obtained
comparing the overall survival (OS) and the progression-
free survival (PFS) of responders and non-responders for
each response assessment tool (PET/CT, CT, or S-100B;
Figs. 1 and 2). Statistical significance was assessed with the
log-rank test and Chi-Square tests. P<0.05 was considered
to indicate a significant difference (Figs. 3 and 4).
Fig. 1 Overall survival of 18F-FDG-PET/CT (a), CT (b) and S-100B
(c) responders and non-responders

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Fig. 2 Progression-free survival of 18F-FDG-PET/CT (a), CT (b) and
S-100B (c) responders and non-responders
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Results
SUV max of the most active metastases showed median
values of 6.8 (mean 10.52; range 1.2–40.0) before therapy
and 5.5 (10.58; 1.2–52.6) after three cycles of chemotherapy.
Eighteen of 25 patients had died after a mean follow-up of
14 months (median 14, range 4–34 months). Advanced mel-
anoma was the cause of death in all the patients (Figs. 3, 4).
Seven patients were alive, four in complete remission (nos.
4, 5, 12, 16) and three with progressive disease (nos. 7, 18,
21). Mean follow-up time in the surviving patients was
18 months (range 14–28 months). Median overall survival
was 18 months in PET/CT responders (n=10) and
11 months in PET/CT non-responders (n=15; p=0.072,
log-rank test). One-year survival was 80% and 40%,
respectively. Thus, 1-year-survival was significantly better
in responders compared with non-responder (p=0.048, chi-
square test). Median progression-free survival was 9 months
in PET/CT responders and 3 months PET/CT non-respond-
ers (p=0.002).
In 11/25 patients, S-100B values could not be used for
follow-up: in three patients, S-100B was not performed,
and in the remaining eight patients, S-100B values were not
suitable for response assessment because they were negative
Fig. 3 A 46-year-old female patient (no. 2) with a melanoma resected
at the flank 1 year before (Breslow 1.7 mm). After detection of lung
and mediastinal metastases in the baseline 18F-FDG-PET (a) with an
increased S-100B (0.6 μg/l) the patient received temodal chemother-
apy. Follow-up 18F-FDG-PET/CT (b) showed a partial response with
decrease of the size and FDG-uptake in the metastases. Correspond-
ingly S-100B dropped to normal values (0.2 μg/l). The next 18F-FDG-
PET/CT (c) showed a complete response with disappearance of the
metastases and the S-100B remained normal (0.2 μg/l). The last 18F-
FDG-PET/CT (d) showed no extracerebral metastases but raised the
suspicion of brain metastases, which was confirmed by an MRI of the
brain (Fig. 4). S-100B failed to indicate new distant metastases
(0.1 μg/l). The patient received radiotherapy of the brain but died
18 months after the beginning of the chemotherapy and 9 months after
the detection of brain metastases
Fig. 4 A 46-year-old female patient (no. 2) with a melanoma resected
at the flank 1 year before (Breslow 1.7 mm). After detection of lung
and mediastinal metastases in the baseline 18F-FDG-PET (a) with an
increased S-100B (0.6 μg/l) the patient received temodal chemother-
apy. Follow-up 18F-FDG-PET/CT (b) showed a partial response with
decrease of the size and FDG-uptake in the metastases. Correspond-
ingly S-100B dropped to normal values (0.2 μg/l). The next 18F-FDG-
PET/CT (c) showed a complete response with disappearance of the
metastases and the S-100B remained normal (0.2 μg/l). The last 18F-
FDG-PET/CT (d) showed no extracerebral metastases but raised the
suspicion of brain metastases, which was confirmed by an MRI of the
brain (Fig. 4). S-100B failed to indicate new distant metastases
(0.1 μg/l). The patient received radiotherapy of the brain but died
18 months after the beginning of the chemotherapy and 9 months after
the detection of brain metastases
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at baseline (median 0.1 μg/l, mean 0.08 μg/l; range 0.0–
0.2 μg/l) despite the presence of proven distant metastases.
So S-100B was suitable for therapy response assessment in
14 patients: median values of 0.6 μg/l (mean 1.7 μg/l; range
0.3 μg/l–12.6 μg/l) before and 0.5 μg/l (1.3 μg/l; 0.1 μg/l–
7.3 μg/l) after therapy. Nine of these 14 patients showed
response (Fig. 5), and five showed no response. There was
no significant difference in the 1-year survival of S-100B-
responders (56%) and S-100B non-responders (40%; p=
0.77) and no significant correlation with OS (p=0.825) or
PFS (p=0.070). There was agreement between S-100B, CT,
and PET/CT response assessment in 11 of 14 patients. In
three patients (nos. 10, 18, 23), disagreement between
imaging and S-100B was observed: the tumormarker
showed response and PET/CT showed no response (pro-
gression in two cases and stable disease in one case).
However, two of these patients started with a relatively low
S-100B value before therapy and decreased only moder-
ately but more than 30% (0.6 to 0.4 μg/l and 0.3 to
0.2 μg/l). In the third patient, the decrease of S-100B was
more impressive (12.6 to 3.1 μg/l) (Fig. 6). Two of these three
patients died after 6 and 11 months, and one lives since
14 months with a high tumor load and brain metastases.
No patient had brain metastases at the beginning of
systemic therapy. Eleven patients developed brain metasta-
ses during the follow-up period, and brain metastases were
first detected in one of the follow-up PET/CT examinations
in two and by MRI in nine of 11 patients. We observed
seven patients who died for brain metastases, although they
had only a low extracerebral tumor load. One patient had
only brain metastases and otherwise a complete remission
of the extracerebral tumor manifestations 3 months before
he died (no. 8). Overall survival after diagnosis of brain
metastases was very poor with a median OS of 3 months
(range 1 to 4 months). Only one patient was still alive at the
end of the follow-up 8 months after diagnosis of a brain
metastasis.
Discussion
Our data show that 18F-FDG-PET/CT and CT imaging
alone are effective tools for chemotherapy response
assessment in stage IV melanoma patients. Imaging is
superior to serial S-100B measurement for assessing overall
survival.
Despite other data supporting the value of serum S-100B
as a clinical marker for monitoring therapy response of
metastatic melanoma during systemic therapies, a clear
drawback of this tumormarker is the fact that it has a false
negative rate in one third of patients with metastases [7, 28,
29]. In the present study, 36% patients failed to show
elevated S-100B values despite the presence of proven
distant metastases. This is in keeping with a previous study
Fig. 5 A 40-year-old female patient (no. 5) with a melanoma resected
at the arm 6 years ago (Breslow 6.5 mm). Baseline 18F-FDG-PET/CT
(a) showing metastases in the lung, liver and a right adrenal metastasis
with hematoma. S-100B was clearly pathologic with an value of
1.7 μg/l. The patient was treated with temodal and the first follow-up
18F-FDG-PET/CT (b) showed disappearance of the FDG-activity, a
resolving hematoma in the adrenal region and disappearance of the
metastases in the liver and lung. S-100B dropped to 0.2 μg/l. The
patient is alive with persisting complete remission at the 19 months
follow-up
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where 15 of 41 patients (37%) showed a false-negative S-
100B before therapy of metastases [16].
FDG-PET/CT is increasingly used for therapy assess-
ment of different tumors [30]. Current data regarding
therapy assessment of melanoma patients with PET or
PET/CT are limited to case reports showing the effect of
limb perfusion therapy and one study comparing change of
PET/CT findings to change of S-100B values in a mixed
population of stage III and stage IV melanoma patients
during different therapies (surgery or chemotherapy) [16,
17]. To our knowledge, this is the first study comparing S-
100B, FDG-PET/CT, and CT alone for therapy response
assessment by using outcome data.
In many clinical trials, CT remains the imaging modality
of choice for therapy assessment in patients with stage IV
melanoma. The big advantage of PET/CT is that this
method provides the combination of metabolic and mor-
phologic information. A recently published study compared
FDG-PET/CT imaging for N- and M-staging of 250
consecutive melanoma patients with PET alone and CT
alone showed the accuracy of PET/CT for M-staging was
significantly higher than that of PET alone and CT alone
(98% vs. 93% and 84%) [5]. We share the experience that
PET/CT is clearly superior to CT alone in the staging
situation. Our data in the present study showed complete
agreement in differentiating chemotherapy responders and
non-responders between CT alone and PET/CT. This
contradicts the results in therapy response assessment in
other tumors, especially lymphoma [31] where it has been
shown that metabolic changes precede morphologic
changes qualifying PET for effective therapy response
assessment very early after initiation of the systemic
therapy. Our results should be confirmed with a larger
number of patients because they could have an important
impact on costs: if CT is a prognostic parameter which is as
strong as the more expensive and less available PET/(CT)
in stage IV melanoma patients, a significant reduction of
imaging costs can be made. In support of the PET/CT, we
also want to state that we still use PET/CT for therapy
response assessment because it provides very clear and
convincing images, normally easy to interpret and to
demonstrate in interdisciplinary meetings, thus enjoying a
high acceptance rate by the referring dermatologists and
oncologists in our hospital. Criteria for therapy response
assessment are under debate especially since combined
modalities like PET/CT are being more frequently used.
The simplest method for therapy assessment is a visual
analysis comparing the baseline and post-therapy scans.
Another approach is the use of semiquantitative measure-
ments such as SUV max or average SUV [32]. This
approach takes a little more time if multiple lesions are
present but is highly reproducible and superior to visual
Fig. 6 A 66-year-old male patient (no. 23) after resection of a lumbar
melanoma (Breslow 1.4). First 18F-FDG-PET/CT (a) shows no
metastases. Second 18F-FDG-PET/CT (b) demonstrates lymph node
metastases in the right axilla which were resected. Third 18F-FDG-
PET/CT (c) with postoperative changes in the right axilla without
metastases. Fourth 18F-FDG-PET/CT (d) shows lung and liver
metastases with a corresponding S-100B value of 12.6 μg/l. A
systemic combination therapy with dacarbazine and thalidomide was
started but the fifth 18F-FDG-PET/CT (e) shows progression of the
metastases regarding size and FDG-activity. S-100B pretended a
response with a decrease to 3.1 μg/l. Brain metastases were detected
with MRI and radiation therapy of the brain as well as change to a
second-line chemotherapy was performed. The patient died 3 months
after the last 18F-FDG-PET/CT
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analysis in specific tumors such as recently shown in
lymphoma patients [33]. More sophisticated and time-
consuming measurements like total lesion glycolysis
(TLG) promise to be more exactly to determine the tumor
burden because size and FDG-uptake of all lesions are
assessed. In recently published papers, the TLG approach
failed to show superiority compared with the simpler SUV
measurements [7, 32]. With this paper, we tried to establish
combined therapy response assessment criteria which take
morphologic (CT part) and metabolic (PET part) changes in
account. We think specific PET/CT therapy response
criteria should be evaluated and established for every
specific type of tumor in the future in a way it has been
initiated for therapy assessment in lymphoma [34].
Clinically apparent brain metastases develop in about
18–46% of patients with stage IV disease, and the
prevalence is even much higher in autopsy series of patients
dying from melanoma [35]. One important drawback of
PET/(CT) is the poor sensitivity of approximately 60% in
detecting brain metastases due to the high physiological
uptake in the normal brain [26]. MRI is clearly the imaging
gold standard in the detection of metastases. In our
population, brain metastases were first detected by PET/
CT in two and by MRI or CCT in nine of 11 patients.
Detecting and staging for brain metastases in melanoma
patients is important for choosing individual therapy which
can consist of surgery, radiotherapy, or chemotherapy or
combinations of these strategies [35, 36]. Our data support
the importance of identifying brain metastases because it
seems to be a critical cause of early death and thus an
important prognostic factor [37]. These findings confirm
the suspicion that current chemotherapy is not as able to
treat intracerebral as extracerebral tumors.
Our study has several limitations. This is a retrospective
study which may lead to a selection bias. The number of
patients is limited, a reason why the statistical calculations
should be interpreted carefully. S-100B measurements were
not available in all the patients. The patients received
different types of chemotherapy before the first response
assessment scan was performed. In non-responders or
patients with severe side-effects, therapy was changed to
second- or third-line drugs, which by their nature are not as
effective as first line drugs. In some patients with brain
metastases irradiation of the brain and/or surgery was
performed. In some patients—if downstaging was reached
by systemic therapy—surgery of viable tumor rests was
performed. We evaluated only the first PET/CT scan during
therapy because this was available in all the patients and the
most consistent measurement. We have chosen the time-
point after three cycles of chemotherapy and not an earlier
timepoint for different reasons: PET scans for therapy
response assessment are only reimbursed in Switzerland
with an interval of 60 days or more; in our experience, the
response of melanoma lesions takes more time than in other
tumors like lymphoma. While PET/CT and S-100B
measurements were performed synchronously at fixed time
points during treatment, CT or MR imaging of the brain
was performed only if there was a suspicion for brain
metastases because of unclear PET/CT findings or neuro-
logical symptoms. Autopsy was not performed in all the
patients so the exact causes of death are not known, and
histopathological proof is obviously not available for all
metastases.
In conclusion, our results suggest that 18F-FDG-PET/CT or
CT alone are equally accurate tools to differentiate short-term
responders and non-responders and can be used in clinical
trials for chemotherapy response assessment in stage IV
melanoma patients. PET/CT showed no superiority to CT
alone, but imaging tools were clearly superior to tumor-
marker S-100B therapy response assessment. Additional
brain MRI is mandatory because many patients die due to
brain metastases despite a low extracerebral tumor load.
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